Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: A one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study)

Clinical and Experimental Rheumatology

Volumn 31, Issue 3, 2013, Pages 358-364

  Yazici, Y ^a   Curtis, J R ^b   Ince, A ^c   Baraf, H S B ^d   Lepley, D M ^e   Devenport, J N ^e   Kavanaugh, A ^f  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Center for Rheumatology and Bone Research   (United States)

^e GENENTECH INC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Outcome assessment; Pain; Randomised controlled trial; Rheumatoid arthritis; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PLACEBO; TOCILIZUMAB;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; ROUTINE ASSESSMENT OF PATIENT INDEX DATA; SCORING SYSTEM;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84878347109     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. SMOLEN JS, LANDEWÉ R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
2. PINCUS T, YAZICI Y, SOKKA T, ALETAHA D, SMOLEN JS: Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S179-85.
3. RUBBERT-ROTH A, FINCKH A: Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009; 11: S1.
4. YAZICI Y, KRASNOKUTSKY S, BARNES JP, HINES PL, WANG J, ROSENBLATT L: Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol 2009; 36: 907-13.
5. SEBBA A: Tocilizumab: the first interleukin- 6-receptor inhibitor. Am J Health Syst Pharm 2008; 65: 1413-8.
6. SMOLEN JS, BEAULIEU A, RUBBERT-ROTH A et al.: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a doubleblind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97.
7. EMERY P, KEYSTONE E, TONY HP et al.: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-23.
8. GENOVESE MC, MCKAY JD, NASONOV EL et al.: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968- 80.
9. KREMER JM, BLANCO R, BRZOSKO S et al.: Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63: 609-21.
10. JONES G, SEBBA A, GU J et al.: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88-96.
11. NISHIMOTO N, MIYASAKA N, YAMAMOTO K et al.: Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009; 19: 12-9.
12. YAZICI Y, CURTIS JR, INCE A et al.: Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 2012; 71: 198-205.
13. PINCUS T, STRAND V, KOCH G et al.: An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 2003; 48: 625-30.
14. STRAND V, COHEN S, CRAWFORD B, SMOLEN JS, FOR THE LEFLUNOMIDE INVESTIGATORS GROUPS, SCOTT DL: Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 640-7.
15. SCALI JJ, VISENTINI S, SALOMÓN J et al.: Rapid and deep control of inflammation in rheumatoid arthritis with infliximab and its correlation with acute-phase reactants. Ann N Y Acad Sci 2007: 1110: 389-401.
16. SHERGY WJ, ISERN RA, COOLEY DA et al.: Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002; 29: 667-677.
17. WEISMAN MH, MORELAND LW, FURST DE et al.: Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003; 25: 1700-21.
18. DEN BROEDER A, VAN DE PUTTE L, RAU R et al.: A single dose, placebo controlled study of the fully human anti-tumor necrosis factor- alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis J Rheumatol 2002: 29: 2288-98.
19. SMOLEN J, LANDEWÉ RB, MEASE P et al.: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study: a randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804.
20. GENOVESE MC, BECKER JC, SCHIFF M et al.: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353: 1114-23.